TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03225105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3541
Description: Participants received M3541 orally once per fraction day (FD) for two consecutive calendar weeks (that is, Monday through Friday, with Saturday and Sunday as M3541 holidays).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3541
Description: Participants received M3541 orally once per fraction day (FD) for two consecutive calendar weeks (that is, Monday through Friday, with Saturday and Sunday as M3541 holidays).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3541
Description: Participants received M3541 orally once per fraction day (FD) for two consecutive calendar weeks (that is, Monday through Friday, with Saturday and Sunday as M3541 holidays).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3541
Description: Participants received M3541 orally once per fraction day (FD) for two consecutive calendar weeks (that is, Monday through Friday, with Saturday and Sunday as M3541 holidays).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative Radiotherapy (RT)
Description: Participants received RT dose of 30 Gray (Gy) given in 10 fractions (3 Gy given per fraction day) administered over two consecutive calendar weeks (that is, Monday through Friday, with Saturday and Sunday as RT holidays).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative Radiotherapy (RT)
Description: Participants received RT dose of 30 Gray (Gy) given in 10 fractions (3 Gy given per fraction day) administered over two consecutive calendar weeks (that is, Monday through Friday, with Saturday and Sunday as RT holidays).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative Radiotherapy (RT)
Description: Participants received RT dose of 30 Gray (Gy) given in 10 fractions (3 Gy given per fraction day) administered over two consecutive calendar weeks (that is, Monday through Friday, with Saturday and Sunday as RT holidays).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative Radiotherapy (RT)
Description: Participants received RT dose of 30 Gray (Gy) given in 10 fractions (3 Gy given per fraction day) administered over two consecutive calendar weeks (that is, Monday through Friday, with Saturday and Sunday as RT holidays).
Study: NCT04316871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.5 mg of Morphine Sulfate
Description: 1.5 mg of Morphine Sulphate will be given epidurally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline will be given epidurally.
Study: NCT02175433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS67E
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS67E
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS67E
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS67E
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS67E
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS67E
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS67E
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS67E
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS67E
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS67E
Description: intravenous (IV) infusion
Study: NCT02515773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin - to achieves maximum insulin-sensitizing effects

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: healthy lifestyle intervention (LIFE)
Description: Healthy Life style intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: healthy lifestyle intervention (LIFE)
Description: Healthy Life style intervention
Study: NCT01764204

Intervention type: DRUG
Intervention: Qingkailing Injection
Description: Qingkailing Injection is a kind of natural product injection made from Chinese herbs, which has been used to treat cerebral ischemia for decades in China. The main bioactive ingredients of this injection include Baicalin, Jasminoidin, Ursodeoxycholic Acid, Concha Margaritifera,etc.
Study: NCT01218620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Given PO
Study: NCT00611585

Intervention type: DEVICE
Group type: OTHER
Intervention: Birmingham Hip Resurfacing
Description: Hip resurfacing system: single use device for hybrid fixation in patients requiring primary hip resurfacing arthroplasty
Study: NCT01218620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolbutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolbutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolbutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolbutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan Hydrobromide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan Hydrobromide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan Hydrobromide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan Hydrobromide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04526678

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron supplement (27mg)
Description: The participants will be randomized to an intervention group or a control group. The intervention group will ingest 27mg iron daily for three months.
Study: NCT01348542

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: 50 mg once a day, for 3 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: The CBT Protocol is implemented over a period of 12 weeks, with 4 consultations held on a weekly basis and 4 held on a biweekly basis.
Study: NCT00747747

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Saline solution
Description: 3 sprays per nostrils twice a day (morning and evening); in case of need a third nebulization between the two is allowed

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sinuclean DM Spray
Description: 3 sprays per nostrils twice a day (morning and evening); in case of need a third nebulization between the two is allowed
Study: NCT04177810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab (350 mg) will be administered IV on day 1 of each cycle (21 day cycle) for up to 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Plerixafor (80mcg/kg/hr) will be administered as a continuous IV infusion of the first 7 days of each cycle (21 day cycle) for up to 2 years.
Study: NCT01563432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Feburic®
Description: 80 mg\*1 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Feburic®
Description: 80 mg\*1 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMX-67
Description: 40 mg\*2 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMX-67
Description: 40 mg\*2 tablets
Study: NCT03031457

Intervention type: DIAGNOSTIC_TEST
Intervention: Duplex ultrasound
Description: Duplex ultrasound of lower extremity venous system
Study: NCT04314427

Intervention type: PROCEDURE
Intervention: Roux-en-Y gastric bypass

Intervention type: PROCEDURE
Intervention: Sleeve gastrectomy
Study: NCT01507831

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for alirocumab)
Description: Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid-Modifying Therapy (LMT)
Description: Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lipid-Modifying Therapy (LMT)
Description: Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
Study: NCT03729752

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [89]Zr-DFO-VRC-HIVMAB060-00-AB
Description: Radiolabeled monoclonal antibody that targets the envelope protein of HIV-1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [89]Zr-DFO-VRC-HIVMAB060-00-AB
Description: Radiolabeled monoclonal antibody that targets the envelope protein of HIV-1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [89]Zr-DFO-VRC-HIVMAB060-00-AB
Description: Radiolabeled monoclonal antibody that targets the envelope protein of HIV-1.
Study: NCT01851590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resin Lacquer
Description: 30% Resin Lacquer is applied once daily for 9 months (Abicin®) in toenail onychomycosis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amorolfine
Description: 5% Amorolfine Lacquer is applied once weekly for 9 months (Loceryl®) in toenail onychomycosis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbinafine
Description: 250 mg of Terbinafine is taken orally once daily for 3 months (Generics) in toenail onychomycosis.
Study: NCT00977964

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental milk protein infant formula Process A
Description: ad lib for 1-8 days of age until 28 days of age

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental milk protein infant formula Process B
Description: ad lib from 1-8 days of age until 28 days of age

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental milk protein infant formula Process C
Description: ad lib from 1-8 days of age to 28 days of age

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental milk protein infant formula Process D
Description: ad lib from 1-8 days of age until 28 days of age

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental milk protein infant formula Process E
Description: ad lib from 1-8 days of age until 28 days of age

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental milk protein infant formula Process F
Description: ad lib from 1-8 days of age until 28 days of age
Study: NCT00623623

Intervention type: PROCEDURE
Group type: OTHER
Intervention: primary PCI
Description: Standard primary PCI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enoxaparin
Description: Adjunctive treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: catheterisation
Description: Routine or rescue coronary intervention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenecteplase
Description: Single, weight-adjusted i.v. bolus of tenecteplase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: Adjunctive treatment
Study: NCT06371716

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ex-vivo RFA under US control at 10 Watts (W) of power in 3 differents arms of lesions
Description: 5 PDAC with neoadjuvant chemotherapy treated at 10 W with ex-vivo RFA 5 PDAC without previous neoadjuvant chemotherapy treated at 10 W with ex-vivo RFA 5 NET treated at 10 W with ex-vivo RFA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ex-vivo RFA under US control at 10 Watts (W) of power in 3 differents arms of lesions
Description: 5 PDAC with neoadjuvant chemotherapy treated at 10 W with ex-vivo RFA 5 PDAC without previous neoadjuvant chemotherapy treated at 10 W with ex-vivo RFA 5 NET treated at 10 W with ex-vivo RFA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ex-vivo RFA under US control at 10 Watts (W) of power in 3 differents arms of lesions
Description: 5 PDAC with neoadjuvant chemotherapy treated at 10 W with ex-vivo RFA 5 PDAC without previous neoadjuvant chemotherapy treated at 10 W with ex-vivo RFA 5 NET treated at 10 W with ex-vivo RFA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ex-vivo RFA under US control at 30 Watts (W) of power in 3 differents arms of lesions
Description: 5 PDAC with neoadjuvant chemotherapy 5 PDAC without previous neoadjuvant chemotherapy 5 NETs

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ex-vivo RFA under US control at 30 Watts (W) of power in 3 differents arms of lesions
Description: 5 PDAC with neoadjuvant chemotherapy 5 PDAC without previous neoadjuvant chemotherapy 5 NETs

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ex-vivo RFA under US control at 30 Watts (W) of power in 3 differents arms of lesions
Description: 5 PDAC with neoadjuvant chemotherapy 5 PDAC without previous neoadjuvant chemotherapy 5 NETs

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ex-vivo RFA under US control at 50 Watts (W) of power in 3 differents arms of lesions
Description: 5 PDAC with neoadjuvant chemotherapy 5 PDAC without previous neoadjuvant chemotherapy 5 NETs

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ex-vivo RFA under US control at 50 Watts (W) of power in 3 differents arms of lesions
Description: 5 PDAC with neoadjuvant chemotherapy 5 PDAC without previous neoadjuvant chemotherapy 5 NETs

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ex-vivo RFA under US control at 50 Watts (W) of power in 3 differents arms of lesions
Description: 5 PDAC with neoadjuvant chemotherapy 5 PDAC without previous neoadjuvant chemotherapy 5 NETs
Study: NCT01902134

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo single oral dose (first 8 hours)

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo single oral dose (first 8 hours)

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo single oral dose (first 8 hours)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol-single dose
Description: Tramadol single oral dose (first 8 hours)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen-single dose
Description: Dexketoprofen single oral dose (first 8 hours)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexketoprofen/Tramadol-single dose
Description: Dexketoprofen/Tramadol oral single dose (first 8 hours)

Intervention type: DRUG
Group type: OTHER
Intervention: Tramadol-multiple doses
Description: Tramadol multiple oral doses t.i.d. for 5 days (total 12 doses)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol-multiple doses
Description: Tramadol multiple oral doses t.i.d. for 5 days (total 12 doses)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen-multiple doses
Description: Dexketoprofen multiple oral doses t.i.d. for 5 days (total 12 doses)

Intervention type: DRUG
Group type: OTHER
Intervention: Dexketoprofen-multiple doses
Description: Dexketoprofen multiple oral doses t.i.d. for 5 days (total 12 doses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexketoprofen/Tramadol-multiple doses
Description: Dexketoprofen/Tramadol multiple oral doses t.i.d. for 5 days (total 12 doses)

Intervention type: DRUG
Group type: OTHER
Intervention: Dexketoprofen/Tramadol-multiple doses
Description: Dexketoprofen/Tramadol multiple oral doses t.i.d. for 5 days (total 12 doses)
Study: NCT01122472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Daily for 3 weeks every 4 weeks for 24 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily for 3 weeks every 4 weeks for 24 months
Study: NCT02868281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT guided Routine Treatment
Description: The ACT is a validated, short, easy to use, and self-administered instrument used to assess asthma control. Subjects in this group received routine treatment as per ACT score.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Routine Treatment
Description: Subjects in the controlled treatment group will receive usual care of asthma. This treatment was monitored and adjusted as usual by the patient's general practitioner.
Study: NCT03374137

Intervention type: BIOLOGICAL
Intervention: obinutuzumab
Description: Obinutuzumab 1000 mg solution used for infusion according to routine clinical practice.
Study: NCT04317833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSS17
Description: SSS17 is a novel small molecule compound which stimulates erythropoiesis through inhibition of hypoxia-inducible factor- prolyl hydroxylases( HIF-PH). It is being developed for the treatment of anemia in patients with chronic kidney disease.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matched placebo
Study: NCT03096574

Intervention type: OTHER
Intervention: Questionnaire
Description: The participants will be approached by a member of the study team and, following recruitment, participants will be asked to fill in a short paper or online questionnaire. Our estimated time for completion is 5-10 minutes, and this time will be stated at the start of the questionnaire. Having completed the questionnaire they will be free to leave without further follow up, and given the contact details of the investigators/research governance office whom they can contact if they have further questions or concerns.
Study: NCT01814137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: For subcutaneous (s.c., under the skin) administration twice daily in combination with up to 2 oral antidiabetic drugs (OADs- dose and dosing frequency of OAD should remain unchanged).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: For subcutaneous (s.c., under the skin) administration once daily in combination with up to 2 oral antidiabetic drugs (OADs- dose and dosing frequency of OAD should remain unchanged).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: For subcutaneous (s.c., under the skin) administration once daily. Dose of IDegAsp and IAsp are individually adjusted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: For subcutaneous (s.c., under the skin) administration three times a day. Dose of IDeg and IAsp are individually adjusted.
Study: NCT01613131

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirena
Description: Mirena (levonorgestrel-releasing intrauterine system), 52 mg (20 mcg/day), 5 year duration (study duration 6 months).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mirena
Description: Mirena (levonorgestrel-releasing intrauterine system), 52 mg (20 mcg/day), 5 year duration (study duration 6 months).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol
Description: Topical, .06%, Applied once daily for 50 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: Topical Gel, Applied once daily for 50 days, Placebo comparator.
Study: NCT00367666

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI, Digital Mammography, Ultrasound and Positron Emission Tomography (PET)
Study: NCT04042974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vaginal dinoprostone
Description: 1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
Study: NCT04917900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib combined with albumin-bound paclitaxel and trastuzumab
Description: Pyrotinib: 400mg, po,qd,with warm water within 30 minutes after breakfast, q3weeks, 6 cycles in total. Albumin-bound paclitaxel: 260mg/m2, iv, Day1, q3weeks, 6 cycles in total. Trastuzumab: The first cycle dose is 8mg/kg, and each subsequent cycle is 6mg/kg, iv, Day 1, q3weeks, a total of 6 cycles.
Study: NCT00931853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SENNA+CASSIA(Naturetti)
Description: Daily administration (oral) of one spoon (5g) of Naturetti (SENNA+CASSIA) jelly sugar free at bedtime, during 30 days
Study: NCT02423174

Intervention type: PROCEDURE
Intervention: Total Mesorectal Excision
Description: Surgical intervention with the FMwand Surgical System

Intervention type: DEVICE
Intervention: FMwand Surgical System
Study: NCT02199652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04316871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3 mg of Morphine Sulfate
Description: 3 mg of Morphine Sulphate will be given epidurally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4.5 mg of Morphine Sulfate
Description: 4.5 mg of Morphine Sulphate will be given epidurally.